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In [Table 2](#t2){ref-type="table"} of the article above, an asterisk was missing denoting a significant difference between the 1,000 mg metformin b.i.d. group and placebo. The corrected table appears on the following page. The online version reflects these changes.

Table 2Efficacy end points following a meal tolerance testParameterPlaceboSitagliptin 100 mg q.d.Metformin 500 mg b.i.d.Metformin 1,000 mg b.i.d.Sitagliptin 50 mg + metformin 500 mg b.i.d.Sitagliptin 50 mg + metformin 1,000 mg b.i.d.2-h PPG (mg/dl)    *n*129136141138147152    Baseline276.8 ± 66.7285.4 ± 82.8292.7 ± 74.6283.4 ± 81.8291.8 ± 84.6286.9 ± 76.2    Week 24281.3 ± 88.2233.8 ± 89.5236.3 ± 70.8207.0 ± 69.4196.3 ± 72.5170.3 ± 58.6    Change from baseline0.3 (−10.4 to 11.0)−51.9 (−62.3 to −41.5)−53.4 (−63.6 to −43.2)−78.0 (−88.3 to −67.6)−92.5 (−102.6 to −82.5)−116.6 (−126.4 to −106.7)    Change from placebo---−52.2 (−67.1 to −37.3)[\*](#t2fn1){ref-type="table-fn"}−53.7 (−68.5 to −38.9)[\*](#t2fn1){ref-type="table-fn"}−78.3 (−93.1 to −63.4)[\*](#t2fn1){ref-type="table-fn"}−92.8 (−107.5 to −78.1)[\*](#t2fn1){ref-type="table-fn"}[†](#t2fn2){ref-type="table-fn"}−116.9 (−131.4 to −102.3)[\*](#t2fn1){ref-type="table-fn"}[†](#t2fn2){ref-type="table-fn"}Glucose AUC (mg · h^−1^ · dl^−1^)    *n*127133144137149146    Baseline523.0 ± 109.4530.2 ± 123.9538.4 ± 116.0532.1 ± 125.6539.9 ± 136.7530.0 ± 120.7    Week 24533.3 ± 146.9453.2 ± 135.3451.3 ± 118.4401.7 ± 120.4383.9 ± 114.0339.0 ± 100.4    Change from baseline6.1 (−11.7 to 23.9)−78.0 (−95.4 to −60.6)−84.4 (−101.1 to −67.7)−130.8 (−147.9 to −113.6)−152.4 (−168.9 to −136.0)−192.3 (−209.0 to −175.7)    Change from placebo---−84.2 (−109.1 to −59.3)[\*](#t2fn1){ref-type="table-fn"}−90.5 (−115.5 to −66.1)[\*](#t2fn1){ref-type="table-fn"}−136.9 (−161.6 to −112.2)[\*](#t2fn1){ref-type="table-fn"}−158.6 (−182.8 to −134.3)[\*](#t2fn1){ref-type="table-fn"}[†](#t2fn2){ref-type="table-fn"}−198.5 (−222.8 to −174.1)[\*](#t2fn1){ref-type="table-fn"}[†](#t2fn2){ref-type="table-fn"}Insulin AUC (μIU · h^−1^ · ml^−1^)    *n*119117130125126133    Baseline76.5 ± 52.971.2 ± 50.280.1 ± 56.484.3 ± 53.679.0 ± 57.274.9 ± 47.2    Week 2475.0 ± 50.378.1 ± 49.383.1 ± 54.682.2 ± 51.486.3 ± 55.774.5 ± 40.6    Change from baseline−1.8 (−7.5 to 3.9)5.2 (−0.6 to 11.0)3.6 (−1.9 to 9.1)−0.4 (−6.0 to 5.2)7.5 (2.0--13.1)−1.1 (−6.5 to 4.4)    Change from placebo---7.0 (−1.2 to 15.1)5.4 (−2.5 to 13.3)1.4 (−6.6 to 9.4)9.4 (1.4--17.3)[‡](#t2fn3){ref-type="table-fn"}0.7 (−7.1 to 8.6)C-peptide AUC (ng · h^−1^ · ml^−1^)125135143138146145    *n*    Baseline9.8 ± 4.39.8 ± 4.310.3 ± 4.110.9 ± 4.39.9 ± 4.310.1 ± 4.1    Week 249.8 ± 4.210.5 ± 4.010.2 ± 4.110.6 ± 4.110.6 ± 4.110.4 ± 4.1    Change from baseline−0.1 (−0.5 to 0.3)0.6 (0.2--1.0)0.0 (−0.4 to 0.4)−0.1 (−0.5 to 0.3)0.6 (0.2--1.0)0.3 (−0.1 to 0.7)    Change from placebo---0.7 (0.1--1.3)[‡](#t2fn3){ref-type="table-fn"}0.1 (−0.5 to 0.7)0.0 (−0.6 to 0.6)0.7 (0.1--1.3)[‡](#t2fn3){ref-type="table-fn"}[§](#t2fn4){ref-type="table-fn"}0.4 (−0.2 to 1.0)Insulin AUC/glucose AUC117115128121125130    *n*    Baseline0.16 ± 0.140.15 ± 0.120.16 ± 0.120.18 ± 0.150.16 ± 0.140.16 ± 0.12    Week 240.16 ± 0.140.19 ± 0.130.20 ± 0.150.23 ± 0.170.24 ± 0.170.23 ± 0.14    Change from baseline0.00 (−0.02 to 0.02)0.04 (0.02--0.05)0.04 (0.02--0.06)0.05 (0.03--0.07)0.08 (0.06--0.10)0.08 (0.06--0.09)    Change from placebo---0.03 (0.01--0.06)[‡](#t2fn3){ref-type="table-fn"}0.04 (0.01--0.06)[‡](#t2fn3){ref-type="table-fn"}0.05 (0.02--0.07)[\*](#t2fn1){ref-type="table-fn"}0.08 (0.05--0.10)[\*](#t2fn1){ref-type="table-fn"}[†](#t2fn2){ref-type="table-fn"}0.07 (0.05--0.10)[\*](#t2fn1){ref-type="table-fn"}[‖](#t2fn5){ref-type="table-fn"}[^1][^2][^3][^4][^5][^6]

[^1]: Data are means ± SD for baseline and week 24 and least-squares mean change (95% CI) for change from baseline or placebo.

[^2]: *P* ≤ 0.001 for the between-group difference relative to placebo.

[^3]: *P* ≤ 0.001 for the between-group difference comparing coadministration and its respective components.

[^4]: *P* ≤ 0.05 for the between-group difference relative to placebo.

[^5]: *P* \< 0.05 for the between-group difference comparing coadministration and metformin 500 mg b.i.d.

[^6]: *P* ≤ 0.05 for the between-group difference comparing coadministration and its respective components. AUC, area under the curve; PPG, postprandial plasma glucose.
